Dotinurad

Generic Name: Dotinurad

Brand Names: 优乐思

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₉Cl_₂NO_₄S

CAS Number: 1285572-51-1

Unique Ingredient Identifier: 305EB53128

Background: Dotinurad is under investigation in clinical trial NCT03372200 (Febuxostat-controlled, Double-blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Fortress Biotech announces FDA approval for Emrosi to treat rosacea and potential approval for cosibelimab for cutaneous squamous cell carcinoma, with financial results and recent corporate highlights for Q3 2024.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy